Form 4: Lixte Biotechnology Director Receives New Stock Options, Some In Lieu of Cash Compensation

Lixte Biotechnology Holdings, Inc. director Stephen J. Forman was granted new stock options, including a portion immediately vesting in exchange for quarterly cash compensation.

Summary

• Stephen J. Forman, a Director and 10% Owner of LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT), reported changes in his beneficial ownership of derivative securities.
• On June 30, 2025, Mr. Forman was granted 10,000 stock options with an exercise price of $0.905 per share, which will vest in eight equal quarterly installments starting September 30, 2025, and expire on June 30, 2030.
• Additionally, on June 30, 2025, Mr. Forman received a grant of 7,754 stock options with an exercise price of $0.905 per share, which vested immediately upon grant and expire on June 30, 2030.
• This grant of 7,754 options was made in lieu of the quarterly cash compensation due to Mr. Forman under the Board Compensation Plan.
• Following these transactions, Mr. Forman directly holds a total of 75,446 options to purchase common stock and indirectly holds 3,772 warrants to purchase common stock through the Stephen Forman Living Trust.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the compensation in lieu of cash, which might suggest financial constraints, and the significantly lower exercise price of new options compared to historical grants, indicating a substantial decline in stock value.

Positives

• The grant of new stock options aligns the director's incentives with the company's stock performance, as the options gain value if the stock price increases.
• The immediate vesting of 7,754 options provides immediate equity ownership to the director.
• The exercise price of the newly granted options ($0.905) is significantly lower than many previously granted options, potentially offering a higher upside if the stock recovers.

Negatives

• The grant of 7,754 options in lieu of quarterly cash compensation may suggest cash flow constraints or a strategic decision to conserve cash by compensating directors with equity.
• The low exercise price of the new options ($0.905) compared to many older options (ranging from $1.21 to $66) indicates a substantial decline in the company's stock price or perceived valuation over time.
• The existence of numerous 'out-of-the-money' options (options with exercise prices significantly above the current grant price of $0.905) suggests that many previously granted options may have limited current value.

Risks

• The issuance of new stock options could lead to future dilution for existing shareholders if these options are exercised.
• Reliance on equity compensation in lieu of cash for directors might signal potential liquidity concerns or a strategic shift in compensation philosophy that could impact future cash management.
• The significant difference between current option exercise prices and historical ones highlights the volatility and potential downside risk associated with the company's stock.

Future Outlook

The document indicates future vesting of 10,000 stock options in eight equal quarterly installments, commencing on September 30, 2025, and expiring on June 30, 2030. No other forward-looking statements or guidance are provided.

Management Comments

• Effective June 30, 2025, the reporting person was granted stock options to purchase an aggregate of 10,000 shares vesting in eight equal installments on the last day of each subsequent quarter until fully vested, with vesting to start on September 30, 2025.
• Effective June 30, 2025, the reporting person was granted stock options in aggregate of 7,754 shares vesting immediately, with the grant being in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.

Industry Context

This Form 4 filing is a standard disclosure of an insider transaction and does not provide broader industry context or trends. It reflects a specific compensation event within Lixte Biotechnology Holdings, Inc.

Comparison to Industry Standards

• This document, an SEC Form 4, is a mandatory disclosure of insider trading activity and does not contain information for direct comparison to industry-wide financial performance benchmarks or specific projects of comparable companies.
• Compensation practices, such as granting stock options in lieu of cash, can vary across the biotechnology industry based on company stage, financial health, and compensation philosophy. Without specific details on Lixte's peer group compensation plans, a direct comparison is not feasible from this document alone.

Corporate Governance

Related Party Transactions

• Stephen J. Forman, a Director and 10% Owner, received stock option grants from LIXTE BIOTECHNOLOGY HOLDINGS, INC. as part of his compensation, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The issuance of new options could lead to future dilution if exercised, but also aligns the director's interests with stock price appreciation. The compensation in stock instead of cash might be viewed positively for cash conservation but negatively if it signals financial distress.
• Management/Directors: Stephen J. Forman receives additional equity compensation, increasing his stake and aligning his financial interests with the company's long-term performance.

Next Steps

• The 10,000 stock options granted on June 30, 2025, will begin vesting in eight equal quarterly installments starting September 30, 2025.

Key Dates

Keywords

LIXTE BIOTECHNOLOGY HOLDINGS, LIXT, SEC Form 4, Insider Transaction, Stock Options, Director Compensation, Beneficial Ownership, Equity Compensation, Biotechnology, Corporate Governance